NAD+ Oral Supplement Pilot Intervention in Adult Females

Completed · Not applicable · Has a placebo group

Conditions studied: Cognitive Change, Inflammation, Neurodegenerative Diseases

In brief

The goal of this clinical trial is to learn whether Nicotinamide adenine dinucleotide (NAD+) can influence cognition and biomarkers in healthy, cognitively intact women aged 40-80. The main questions it aims to answer are: Will cognitive functioning change in response to NAD+? Will inflammatory markers and serum indicators of neurodegeneration change in response to NAD+? Researchers will compare individuals receiving NAD+ to those receiving placebo to see if the results differ. Participants will: Complete an online questionnaire, Visit the lab for computerized cognitive testing and a blood draw, Take NAD+ or a placebo every day for 4 weeks, Visit the lab for computerized cognitive testing and a blood draw

Key facts

Study ID

NCT06579209

Run by

University of Rhode Island

People needed

53

Starts

2024-12-01

Expected to finish

2026-02-20

Last updated by the study team

2026-03-12

Who can join

Age: 40 and older, up to 80. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Identify as Female
• Have a BMI of 18.5 or above
• Must be able to swallow tablets

You may not qualify if…

• Those who are pregnant, breastfeeding, or taking hormone medication

Where it is running

• University of Rhode Island — Kingston, Rhode Island, United States
• Independence Square, University of Rhode Island — Pawtucket, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.